Company intelligence / Profile preview

AI4LYF

Ownership: Private
Development stage: Other

Overview

AI4LYF's Digital Cough Technology (DCT) is licensed to Therma Bright and being piloted as a respiratory disease screening and monitoring tool. Its platforms enable continuous, predictive, and remote health diagnostics via biosensors and AI. DCT is currently being considered for use in a chronic cough drug clinical trial and for public health applications in respiratory disease detection[2][3].

Therapeutic areas: PulmonologyOther
Modalities: DeviceDigital diagnostic platformMobile health app
Industry: Physiological Monitoring

Partnerships

Therma Bright

Beyond the preview

Go deeper on AI4LYF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI4LYF.

Explore the full profile